Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16221363 | 0.83 | DHFR (0.51) | DHFRTMEM97SIGMAR1PTGDR2KDR | |
| SCHEMBL16210173 | 0.83 | TMEM97 (0.52) | DHFRTMEM97SIGMAR1PTGDR2KDR | |
| SCHEMBL16379833 | 0.83 | DHFR (0.51) | DHFRTMEM97SIGMAR1PTGDR2KDR | |
| SCHEMBL3340495 | 0.80 | TMEM97 (0.49) | DHFRTMEM97SIGMAR1PTGDR2KDR | |
| SCHEMBL16220576 | 0.76 | DHFR (0.53) | DHFRTMEM97SIGMAR1PTGDR2KDR | |
| SCHEMBL17327930 | 0.75 | DHFR (0.52) | DHFRTMEM97SIGMAR1PTGDR2KDR | |
| SCHEMBL16210333 | 0.75 | TMEM97 (0.53) | DHFRTMEM97SIGMAR1PTGDR2KDR | |
| SCHEMBL16210658 | 0.74 | TMEM97 (0.52) | DHFRTMEM97SIGMAR1PTGDR2KDR | |
| SCHEMBL183613 | 0.74 | PDE10A (0.44) | — | |
| SCHEMBL16379829 | 0.74 | DHFR (0.50) | DHFRTMEM97SIGMAR1PTGDR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991989-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-9145427-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329820-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | DHFR 388/4885TMEM97 3393/4885SIGMAR1 573/4885 |
| US-20150353579-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | DHFR 388/4885TMEM97 3393/4885SIGMAR1 573/4885 |
| US-20150080401-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | DHFR 388/4885TMEM97 3393/4885SIGMAR1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.